We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+2.09%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$297M
AUM Growth
+$56.9M
(+24%)
Cap. Flow
+$55.4M
Cap. Flow
% of AUM
18.67%
Top 10 Holdings %
Top 10 Hldgs %
80.3%
Holding
232
New
27
Increased
80
Reduced
67
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MBS ETF
MBB
|
+$25.2M |
| 2 |
Invitation Homes
INVH
|
+$6.9M |
| 3 |
American Homes 4 Rent
AMH
|
+$3.4M |
| 4 |
LAZR
Luminar Technologies
LAZR
|
+$1.51M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$1.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Globus Medical
GMED
|
+$978K |
| 2 |
Omnicell
OMCL
|
+$641K |
| 3 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
+$568K |
| 4 |
RAVN
Raven Industries Inc
RAVN
|
+$373K |
| 5 |
NNDM
Nano Dimension
NNDM
|
+$287K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.29% |
| 2 | Healthcare | 13.15% |
| 3 | Technology | 2% |
| 4 | Industrials | 1.37% |
| 5 | Consumer Discretionary | 1.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Vertex Pharmaceuticals
VRTX
$123B
| $860K | 0.29% |
4,000
+2,950
| +281% | +$648K |
|
|
NNDM
27
Nano Dimension
NNDM
$318M
| $859K | 0.29% |
100,000
-25,000
| -20% | -$287K |
|
|
VIRX
28
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $855K | 0.29% |
+92,402
| New | +$963K |
|
29
Microbot Medical
MBOT
$120M
| $851K | 0.29% |
100,000
| – | – |
|
30
Cogent Biosciences
COGT
$6.62B
| $790K | 0.27% |
90,000
+70,300
| +357% | +$677K |
|
31
AgEagle Aerial Systems
UAVS
$41.4M
| $783K | 0.26% |
+125
| New | +$1.17M |
|
32
Gilead Sciences
GILD
$166B
| $763K | 0.26% |
11,800
| – | – |
|
33
Sarepta Therapeutics
SRPT
$1.81B
| $708K | 0.24% |
9,500
+8,775
| +1,210% | +$810K |
|
34
Kohl's
KSS
$1.96B
| $674K | 0.23% |
11,299
-381
| -3% | -$19.6K |
|
|
YMAB
35
DELISTED
Y-mAbs Therapeutics
YMAB
| $665K | 0.22% |
22,000
+19,000
| +633% | +$779K |
|
|
CYBE
36
DELISTED
Cyberoptics Corp
CYBE
| $649K | 0.22% |
25,000
| – | – |
|
|
APLT
37
DELISTED
Applied Therapeutics
APLT
| $619K | 0.21% |
+33,000
| New | +$712K |
|
38
BioMarin Pharmaceuticals
BMRN
$11.5B
| $604K | 0.2% |
8,000
+500
| +7% | +$40.8K |
|
39
Legend Biotech
LEGN
$4.44B
| $580K | 0.2% |
+20,000
| New | +$546K |
|
40
Axsome Therapeutics
AXSM
$11.8B
| $566K | 0.19% |
+10,000
| New | +$703K |
|
41
Karyopharm Therapeutics
KPTI
$178M
| $547K | 0.18% |
3,467
+2,334
| +206% | +$492K |
|
|
ZGNX
42
DELISTED
Zogenix, Inc.
ZGNX
| $527K | 0.18% |
27,000
+11,500
| +74% | +$236K |
|
43
Celldex Therapeutics
CLDX
$2.79B
| $515K | 0.17% |
25,000
+21,500
| +614% | +$494K |
|
44
Incyte
INCY
$23.2B
| $508K | 0.17% |
6,250
+3,750
| +150% | +$320K |
|
45
Invesco
IVZ
$13.3B
| $503K | 0.17% |
19,943
-531
| -3% | -$11.9K |
|
46
MGM Resorts International
MGM
$12B
| $497K | 0.17% |
13,088
-441
| -3% | -$15.4K |
|
|
MRSN
47
DELISTED
Mersana Therapeutics
MRSN
| $493K | 0.17% |
1,220
+1,036
| +563% | +$503K |
|
|
ASXC
48
DELISTED
Asensus Surgical, Inc.
ASXC
| $488K | 0.16% |
+150,000
| New | +$543K |
|
49
Aurinia Pharmaceuticals
AUPH
$1.99B
| $454K | 0.15% |
35,000
+15,000
| +75% | +$218K |
|
50
iShares Mortgage Real Estate ETF
REM
$555M
| $446K | 0.15% |
12,644
-10
| -0.1% | -$335 |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, AlphaCentric Advisors held 232 positions worth $297M, up 24% from $240M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
AlphaCentric Advisors deployed $55.4M of net new capital in Q1 2021, opening 27 new positions and adding to 80 existing holdings. Its largest new stake was Luminar Technologies: 3,333 shares worth $1.22M.
By sector, the portfolio is most concentrated in Real Estate at 18% of assets, up from 16% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Omnicell, an estimated $641K trimmed.
- AlphaCentric Advisors's largest Q1 2021 buy was Luminar Technologies: 3,333 shares worth $1.22M.
- AlphaCentric Advisors added most to iShares MBS ETF in Q1 2021, an estimated $25.2M increase.
- AlphaCentric Advisors's biggest Q1 2021 reduction was Omnicell, cutting an estimated $641K.
- AlphaCentric Advisors fully exited Globus Medical in Q1 2021, selling an estimated $978K.
- AlphaCentric Advisors's ten largest holdings make up 80% of its $297M portfolio in Q1 2021.
- AlphaCentric Advisors opened 27 new positions and closed 26 in Q1 2021.
- AlphaCentric Advisors's portfolio value rose 24% quarter-over-quarter to $297M.
Based on AlphaCentric Advisors's 13F filing for Q1 2021, filed 9 Mar 2022.